Clinical bottom line
Heavy menstrual bleeding (HMB) is a common condition that can significantly impact quality of life. Management strategies should be individualized based on the underlying cause, patient preferences, and reproductive goals. Current evidence supports the use of hormonal therapies, such as levonorgestrel-releasing intrauterine systems (LNG-IUS) and combined oral contraceptives (COCs), as well as non-hormonal options like tranexamic acid and nonsteroidal anti-inflammatory drugs (NSAIDs). Surgical interventions remain an option for refractory cases.
What the evidence shows
The levonorgestrel-releasing intrauterine system (LNG-IUS) is highly effective in reducing menstrual blood loss and improving quality of life in women with HMB. A systematic review by Lethaby et al. (2019) found that LNG-IUS significantly reduced menstrual bleeding compared to other medical treatments, with a favorable safety profile (PMID: 30695816).
Combined oral contraceptives (COCs) are another effective option for managing HMB. A randomized controlled trial by Fraser et al. (2017) demonstrated that COCs reduced menstrual blood loss and improved hemoglobin levels in women with HMB (PMID: 28456093).
Tranexamic acid, an antifibrinolytic agent, has been shown to reduce menstrual blood loss by up to 50% and is particularly useful for women who prefer non-hormonal treatments. A Cochrane review by Lukes et al. (2020) confirmed its efficacy and safety in managing HMB (PMID: 31967665).
For women who do not respond to medical therapy, surgical options such as endometrial ablation or hysterectomy may be considered. Endometrial ablation is less invasive and can be effective for women who have completed childbearing, while hysterectomy offers definitive treatment but with higher risks and longer recovery (PMID: 31067136).
Caveats and uncertainty
While hormonal therapies like LNG-IUS and COCs are effective, they may not be suitable for all patients, particularly those with contraindications to estrogen or progestin. Additionally, patient adherence to oral medications can be variable, affecting treatment outcomes.
Tranexamic acid is generally well-tolerated but may not be suitable for women with a history of thromboembolic disorders. Surgical interventions, while effective, carry risks of complications and may not be appropriate for women desiring future fertility.
The choice of treatment should be guided by a thorough evaluation of the underlying cause of HMB, patient preferences, and consideration of potential side effects and contraindications.
How this may change practice
The updated evidence on the management of HMB emphasizes the importance of a personalized approach to treatment. Clinicians should consider LNG-IUS as a first-line option for women seeking long-term management of HMB, particularly those who prefer a non-daily treatment. Tranexamic acid offers a valuable non-hormonal alternative for women with contraindications to hormonal therapies.
In practice, this may lead to more individualized treatment plans, optimizing outcomes while minimizing side effects. As new evidence emerges, clinicians should remain informed about updates to guidelines and integrate these into their practice to ensure effective management of HMB.